Talia Kae Parenza, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2453 N Court St, Ottumwa, IA 52501 Phone: 641-684-1853 Fax: 641-683-5949 |
Dr. Mark Alan Hogan Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1140 N Jefferson St, Ottumwa, IA 52501 Phone: 641-684-5467 Fax: 641-683-8364 |
Jonathan Caston, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 107 W Main St, Ottumwa, IA 52501 Phone: 641-684-5453 |
Jennifer Ware Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1940 Venture Dr, Ottumwa, IA 52501 Phone: 641-683-1357 |
Marc Thieme, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1140 N Jefferson St, Ottumwa, IA 52501 Phone: 641-684-5467 |
Adria Wolver, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 107 W Main St, Ottumwa, IA 52501 Phone: 641-684-5453 |
News Archive
Decision Resources, Inc., forecasts that Amgen's novel biological agent for the treatment of osteoporosis, AMG-162, will become a blockbuster by 2013. Premium pricing of AMG-162 will propel the sales of this agent.
Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.
To date, little evidence has been documented regarding the immune responses after the onset of the symptoms or virus detection. Further, no cross-sectional studies have been conducted that define the time of infection. Thereby, no report is available that explains the relationship between the earliest immune responses to COVID-19 and temporal kinetics. New research deals with this research gap using blood transcriptomics, multiparameter flow cytometry, and T cell receptor (TCR) sequencing methods.
A compound found in green tea shows great promise for the development of drugs to treat two types of tumors and a deadly congenital disease. The discovery is the result of research led by Principal Investigator, Dr. Thomas Smith at The Donald Danforth Plant Science Center and his colleagues at The Children's Hospital of Philadelphia.
Drugs that pharmaceutical companies market most aggressively to physicians and patients tend to offer less benefit and more harm to most patients - a phenomenon described as the "inverse benefit law" in a paper from the University of Texas Medical Branch at Galveston.
› Verified 8 days ago